tetano
Editor, Senior Moderator
Paediatr Child Health. 2018 Feb;23(1):31-34. doi: 10.1093/pch/pxx195. Epub 2018 Jan 15.
[h=1]Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?[/h] Tam TWS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Canada and the USA differ in their recommendations for the use of live attenuated influenza vaccine (LAIV). The Canadian National Advisory Committee on Immunization (NACI) continues to recommend LAIV as one of the influenza vaccines available for use in children 2 to 17 years of age. The US Advisory Committee on Immunization Practices (ACIP) made an interim recommendation against the use of LAIV for the 2016 to 2017 influenza season in response to low LAIV effectiveness observed in the USA during the 2013 to 2014 to 2015 to 2016 seasons. The recommendation has been continued for the 2017 to 2018 season. In response, NACI undertook a review of available LAIV effectiveness data in children and adolescents from Canada, the USA and a number of European countries. This commentary by Canada's Chief Public Health Officer summarizes the findings of that review and provides the rationale for Canada's current continued recommendation for LAIV use.
PMID: 29479277 PMCID: PMC5815092 [Available on 2019-02-01] DOI: 10.1093/pch/pxx195
[h=1]Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?[/h] Tam TWS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Canada and the USA differ in their recommendations for the use of live attenuated influenza vaccine (LAIV). The Canadian National Advisory Committee on Immunization (NACI) continues to recommend LAIV as one of the influenza vaccines available for use in children 2 to 17 years of age. The US Advisory Committee on Immunization Practices (ACIP) made an interim recommendation against the use of LAIV for the 2016 to 2017 influenza season in response to low LAIV effectiveness observed in the USA during the 2013 to 2014 to 2015 to 2016 seasons. The recommendation has been continued for the 2017 to 2018 season. In response, NACI undertook a review of available LAIV effectiveness data in children and adolescents from Canada, the USA and a number of European countries. This commentary by Canada's Chief Public Health Officer summarizes the findings of that review and provides the rationale for Canada's current continued recommendation for LAIV use.
PMID: 29479277 PMCID: PMC5815092 [Available on 2019-02-01] DOI: 10.1093/pch/pxx195